

1. OPINION COLUMN: [Is IPR moral?](#)**– Business Today**

The world power now uses the IPR treaty to force these countries to pay its companies if they want to eat food grain anymore. IPR is defended most often on the basis that it promotes human welfare through economic advancement. We view IPR from the prism of their economic outcomes. Is protecting IPR more economically efficient? Will it bring better and faster innovation?

2. [Clause for evergreening of patents dropped from RCEP: Nirmala Sitharaman](#) – Business Standard

A patent on the new form would give the innovator company a 20-year monopoly on the drug.

Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed on Monday.

"It may be noted that some RCEP countries had tried to introduce a clause in favour of evergreening of patents, which was dropped after stiff opposition from India," Commerce and Industry Minister Nirmala Sitharaman said in a written reply to the Lok Sabha.

Similar report-

[India's new stance at RCEP may benefit China](#) – Mint

3. [Govt amends clinical trial procedures to lure drug makers](#) – Hindustan Times

With more and more drug makers scouting for manufacturing hubs in foreign lands, the government has decided to ease clinical trial procedures in India. The apex body to control clinical trials and drug quality issues, the Drug Controller General of India (DCGI), has amended some critical clauses.

The government, as per the draft issued on August 4, has taken several measures such as removal of restrictions on the number of trials to be conducted at a given point of time. Due to the increasing number of deaths during trials, the government had earlier imposed a restriction of not more than three clinical trials to be conducted by an investigator. Restrictions on number of minimum beds at the clinical trial site have also been removed. Earlier, the clinical trial site was mandated to have at least 50 beds.

1. OPINION PIECE: [Is IPR moral?](#) – Business Today
2. [Clause for evergreening of patents dropped from RCEP: Nirmala Sitharaman](#) – Business Standard
3. [Govt amends clinical trial procedures to lure drug makers](#) – Hindustan Times
4. [Not all are equal: Where health coverage lags behind](#) – The Hindu
5. [Aurobindo Pharma gets USFDA nod for anti-infective injection](#) – The Economic Times
6. [Glenmark Pharma gains after receiving USFDA approval for Kenalog generic](#) - Business Standard
7. [WHO for dengue vaccine in India](#) – The Times of India
8. [Rajya Sabha passes 'patient-centric' Mental Health Care Bill 2013](#) – Hindustan Times
9. [Delhi grapples with rise in prescription drug abuse, chemist shops under close watch](#) – Indiatoday.in
10. [Desi Devices Too Get An entry Into Indian Medical Tenders Finally](#) – Businessworld.in
11. [PCI working with ministry of C&F to open 600 Jan Aushadhi stores in pharmacy colleges](#) – Pharmabiz.com

4. [Not all are equal: Where health coverage lags behind](#) – **The Hindu**

India is a land of contrasts, and nowhere is this truer than in its state of healthcare. With vast variances in the access to and affordability of healthcare across different States, and vivid differences between private and public healthcare and rural and urban health systems, it is necessary to take a view that will not allow the averages to overwhelm the true picture.

India faces daunting healthcare challenges. Despite gradual progress in improving access to health systems, including a meticulously planned National Rural Health Mission (NRHM), the twin conundrums of access and affordability remain.

5. [Aurobindo Pharma gets USFDA nod for anti-infective injection](#) – **The Economic Times**

Aurobindo Pharma has received approval from the US health regulator to make and market its anti-infective Linezolid injection in the American market. "The company has received final approval from the United States Food & Drug Administration (USFDA) to manufacture and market Linezolid injection, 600 mg/300 mL (2 mg/mL)," Aurobindo said in a filing to BSE. It is expected to be launched in the second quarter of the 2016-17 fiscal, and is the generic version of of Pharmacia & Upjohn Company's Zyvox injection in the same strength.

Also appeared in-

[Aurobindo Pharma receives US FDA nod for anti-infective drug](#) – Business Standard

6. [Glenmark Pharma gains after receiving USFDA approval for Kenalog generic](#) - **Business Standard**

Glenmark Pharmaceuticals rose 0.71% to Rs 848.85 at 9:30 IST on BSE after the company said it received final approval for Triamcinolone Acetonide cream. Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Glenmark said that its current portfolio consists of 108 products authorized for distribution in the US marketplace and 61 Abbreviated New Drug Application (ANDA) pending approval With the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

7. [WHO for dengue vaccine in India](#) – **The Times of India**

As dengue cases show a steep increase, particularly in Delhi, the World Health Organisation (WHO) has recommended introducing dengue vaccine in high burden countries like India. Two months ago, the apex committee on health, headed by the health secretary, had denied approval to a multinational firm for its dengue vaccine when it sought a clinical trial waiver in India.

In May, the committee had concluded that the data presented by the company was inadequate to show the efficacy and immunogenicity of the vaccine in Indians. Immunogenicity is the ability of a substance to provoke an immune response in the body.

8. [Rajya Sabha passes 'patient-centric' Mental Health Care Bill 2013](#) – **Hindustan Times**

The Rajya Sabha on Monday unanimously passed the Mental Health Care Bill 2013, which seeks to provide better healthcare to people with mental illness and safeguard their rights.

The bill gives one the right to select a representative, who will design the mode of treatment according to which the person will be treated if he/she gets diagnosed with a mental illness.

"This person would be a nominative representative, who has a similar cultural background as the patient and is aware of his likes and dislikes," said Union health minister JP Nadda, while introducing the bill.

9. [Delhi grapples with rise in prescription drug abuse, chemist shops under close watch](#) – **Indiatoday.in**

Delhi government is taking action and putting stricter measures in place for rising pharmaceutical drug abuse in the city. Delhi has approximately 6000 chemist stores, and the

government has banned 15 stores for selling medicines without prescriptions in the past year. Prescription drug abuse is at an all time high, with Narcotics Control Burea's 2015 report stating that abuse has assumed "serious proportions" and the problem being more serious in Northeast and Northwest regions in India.

10. [Desi Devices Too Get An entry Into Indian Medical Tenders Finally](#) – Businessworld.in

The desi medical devices makers can now make their way into various healthcare tenders floated by government hospitals across the country. The union ministry of health and family welfare has asked them to include and encourage domestic standards for procurement of medical devices in tender specifications by various health agencies. On behalf of the ministry, additional secretary K B Agarwal has last week issued an advisory to all state governments and central health agencies to include medical devices approved by India's drugs control authority Central Drug Standards Control Organization (CDSCO) for being considered for procurement and desist from insistence of US Food and Drug Administration approvals.

11. [PCI working with ministry of C&F to open 600 Jan Aushadhi stores in pharmacy colleges](#) – Pharmabiz.com

The Pharmacy Council of India (PCI) is working with ministry of chemical and fertilizers to promote Jan Ausadhi Scheme by establishing 500 to 600 Jan Ausadhi stores in approved pharma colleges across the country for the availability of quality medicines at affordable prices.

The Council believes that the initiative will serve both the purpose of requirement of quality medicine at affordable price as well as the requirement of practical training to the student pharmacists as under the provisions of the 'the education regulations, 1991' and 'the bachelor of pharmacy course regulation, 2014'. There is a statutory requirement for students to undergo practical training in a pharmacy practice in hospital or community pharmacy. Hence by becoming a partner to Prime Minister's Jan Aushadhi Yojna (PMJAY), pharmacy institutions will fulfill the requirement.